Evidence mapPaperPMID 41244044Full record

ReviewFrontiers in endocrinology2025

The gut-adipose/pancreas axis: a novel perspective on glycolipid metabolism dysregulation in MAFLD and T2DM pathogenesis.

Jiahui Liang, Yunhang Chu, Xingyu Chen, Yan Leng

Erratum issuedAbstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Jiahui LiangGastroenterology, Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China.
Yunhang ChuGastroenterology, Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China.
Xingyu ChenDepartment of Liver, Spleen and Gastroenterology, Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China.
Yan LengDepartment of Liver, Spleen and Gastroenterology, Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic-associated fatty liver disease (MAFLD) and type 2 diabetes mellitus (T2DM) frequently co-exist on the pathological basis of dysregulated glucose and lipid metabolism, forming a bidirectional causal relationship. The upstream mechanisms underlying this association require further elucidation. Recent studies suggest that the interactive network comprising the "gut-adipose axis" and "gut-pancreatic axis" represents a core component of the comorbidity mechanism. This network initiates with gut microbiota dysbiosis, which alters short-chain fatty acids (SCFAs), lipopolysaccharide (LPS), branched-chain amino acids (BCAAs), secondary bile acids(SBAs), and other microbial metabolites, as well as endocrine signals such as the endocannabinoid system (ECS) and incretin hormones. This network simultaneously influences adipose tissue and the pancreas to coordinate glucose and lipid homeostasis. Therefore, this paper proposes the "Common Messengers, Dual-Axis Convergence" model to systematically elucidate how the gut microbiota, through a shared set of messenger molecules, simultaneously and independently drives lipid and glucose metabolic dysregulation via the gut-adipose and gut-pancreatic axes, ultimately leading to the comorbidity of MAFLD and T2DM.

Indexed as

Adipose TissueDiabetes Mellitus, Type 2Gastrointestinal MicrobiomeGlycolipidsNon-alcoholic Fatty Liver DiseasePancreasAnimalsHumansLipid MetabolismGlycolipidsglucose and lipid metabolismgut–adipose axisgut microbiotagut–pancreatic axismetabolic-associated fatty liver diseasetype 2 diabetes mellitus

Identifiers

PMID41244044
PMCPMC12615203

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.